SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- DiCello Levitt LLP announces that purchasers or acquirers of GoodRx Holdings, Inc. ("GoodRx" or the "Company") (NASDAQ:GDRX) common stock between September 23, 2020 and November 8, 2022, inclusive (the "Class Period") have until June 21, 2024 to seek appointment as lead plaintiff of the GoodRx class action lawsuit. The GoodRx lawsuit charges the Company and certain senior executive officers with violations of the federal securities laws.
If you purchased shares of GoodRx common stock between September 23, 2020 and November 8, 2022, and suffered substantial losses, and you wish to serve as lead plaintiff in this lawsuit, you may submit your information here: https://dicellolevitt.com/securities/goodrx/
You can also contact DiCello Levitt partner Brian O'Mara by calling (888) 287-9005 or at investors@dicellolevitt.com.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Case Allegations: GoodRx operates a price comparison platform for prescription drugs which, in many cases, offers consumers access to lower prices (through discount codes and coupons) for their medications. GoodRx generates most of its revenue from contracts with pharmacy benefit managers ("PBMs") who ...
GDRX) and Lead Plaintiff Deadline>Full story available on Benzinga.com